Clinical Trial Update: Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating PRN and every-2-months dosing of intravitreal aflibercept for age-related macular degeneration has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)

Snippet

Sponsor: Nihon University | Conditions: Age-related Macular Degeneration | Phase 4 | Status: COMPLETED